![]() ![]() The Auxilium stock is off 14.5% YTD compared to the NASDAQ Biotech index which is up 19% for the same period. This has also led to underperform for the shares of Auxilium Pharmaceuticals, Inc. Category prescription performance of testosterone replacement therapies is up 13% so far in 2013 whereas prescriptions for Testim are down by 14%. The total market for this product is estimated at $2 billion. Androgel is currently offered by AbbVie Inc (NYSE: ABBV) and Eli Lilly & Co. (NYSE: LLY) has Axiron. Analysts have indicated a two-thirds chance of approval and believe this is not reflected in the current valuation of Auxilium.Ĭurrently, other products for men with low testosterone exist. The timeline of a Phase III trial is still uncertain, but if it shows efficacy there, it could act as a positive catalyst for the stock.Īdditionally, the FDA is expected to rule on Xiaflex for the treatment of Peyronies disease. Using the injection for this purpose would add another revenue stream for Auxilium Pharmaceuticals, Inc. The company recently had positive results from its Phase IIa trials with Xiaflex used in the treatment of frozen shoulder syndrome. 1%) that will advance to Phase III trials later in 2013 which could extend the life of the product line. (NASDAQ:AUXL) has responded by developing a follow up to Testim (1.6% concentration vs. ![]() The stock has priced in significant loss of market share to this and other potential generics. Androgel from Teva and Perrigo is one such product. Other similar generic products are expected to enter the market starting in 2015. The patent on Testim currently is set to expire in 2023 and the dismissal of the suit highlights the unlikelihood of a generic reaching the market before that time. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |